MeiraGTx vs Vir Biotechnology
MGTX and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGTX and VIR compare
Vir Biotechnology is the larger company, worth 1.9 times as much as MeiraGTx ($1.7B against $882M).
Vir Biotechnology grew revenue faster over the last twelve months (1696% versus 1366% for MeiraGTx).
MeiraGTx keeps more of each dollar of sales as profit, with a net margin of 19.5% compared with −61.0% at Vir Biotechnology.
Vir Biotechnology scores higher on the StockData Score (12 against 10 for MeiraGTx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGTX | VIR |
|---|---|---|
| Size and price | ||
| Market cap | $882M | $1.7B |
| Share price | $9.18 | $9.96 |
| Change, 1 year | 6.0% | 74.4% |
| Change, 5 years | −50.8% | −69.6% |
| Beta (5Y) | 1.58 | 0.72 |
| Employees | 403 | 367 |
| StockData Score | ||
| Total score | 10 | 12 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 11.5× | – |
| P/S | 2.2× (better) | 5.6× |
| P/B | – | 1.9× |
| EV/EBITDA | 4.3× | – |
| FCF yield | −0.34% (better) | −8.4% |
| Fair value | $27.21 | $12.60 |
| Margin of safety | 66.3% (better) | 21.0% |
| Growth | ||
| Revenue growth (TTM) | 1366% | 1696% (better) |
| Revenue growth, 5Y average | 39.2% (better) | −2.1% |
| Profitability | ||
| Operating margin | 44.8% (better) | −69.8% |
| Net margin | 19.5% (better) | −61.0% |
| FCF margin | −0.74% (better) | −46.8% |
| Return on equity | – | −21.8% |
| Return on invested capital | – | −45.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −0.33 | – |
| Current ratio | 4.62 | 6.30 (better) |
| Altman Z-score | 3.11 (better) | 3.11 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −20.0% | – |
| Shareholder yield | −20.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 82.5% | 86.6% |
| Held by insiders | 35.2% | 17.0% |
| Insider net buying, 12 months | −$4.7M | −$4.0M (better) |
| Short interest, % of float | 10.7% | 12.0% |
Go deeper
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
- VIR stock overview
- VIR income statement
- VIR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.